COVID-19: Chugai’s antibody cocktail therapy approved: casirivimab / imdevimab
Chugai:
New coronavirus infectious disease treatment “RONA PREVE”
Chugai Pharmaceutical Co., Ltd., a domestic distributor, held a briefing session on August 26th.
Intravenous drug “RONA PREVE”:
The infusion drug “RONA PREVE” is approved only for infusion.
Apply for subcutaneous injection:
Regarding the administration method, he revealed his intention to hurry to “apply for change of regulatory approval so that subcutaneous injection can be used”.
In the United States, antibody cocktail therapy, casirivimab / imdevimab, has already been approved.
Chugai expects that “outpatient convenience will increase.”
What is RONAPREVE?
It is a therapeutic drug using antibody cocktail therapy and can be used from mild cases.
FDA approval:
In June of this year, the FDA renewed the Emergency Use Authorization (EUA) for antibody cocktail therapy, casirivimab / imdevimab.
Subcutaneous injection was allowed only for patients who could not be administered by infusion.
The dose is the same as infusion.
Four injections are required per person.
The FDA also approved prophylaxis in July for close contacts at high risk of aggravation.
Mainichi newspaper